SCHEMBL4777484

SCHEMBL4777484

CS(=O)(=O)N(Cc1cccc(Cl)c1Cl)c1ccc(C(=O)NCCC2CCCCN2)cc1

nearest known ligand 0.48

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.46
RECQL P46063 1/20 0.46
ALDH1A1 P00352 5/20 0.46
NPSR1 Q6W5P4 3/20 0.45
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
POLB P06746 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.39
LMNA P02545 2/20 0.39
ITGB3 P05106 1/20 0.39
ITGA2B P08514 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4776728 0.82 ALDH1A1 (0.50) GAARECQLALDH1A1NPSR1KMT2A
SCHEMBL4773331 0.82 RECQL (0.50) GAARECQLALDH1A1NPSR1KMT2A
SCHEMBL4768090 0.81 ALDH1A1 (0.46) GAARECQLALDH1A1NPSR1KMT2A
SCHEMBL4777302 0.81 GAA (0.56) GAARECQLALDH1A1NPSR1KMT2A
SCHEMBL5571358 0.81 ALDH1A1 (0.54) GAARECQLALDH1A1NPSR1KMT2A
SCHEMBL5571747 0.80 ALDH1A1 (0.51) GAARECQLALDH1A1NPSR1KMT2A
SCHEMBL4775082 0.80 GHSR (0.36) ALDH1A1KMT2A
SCHEMBL4777649 0.80 GAA (0.55) GAARECQLALDH1A1NPSR1KMT2A
SCHEMBL5568991 0.80 ALDH1A1 (0.44) GAARECQLALDH1A1NPSR1KMT2A
SCHEMBL5572216 0.80 ALDH1A1 (0.44) GAARECQLALDH1A1NPSR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 GAA 466/4885RECQL 139/4885ALDH1A1 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.